Erythropoietin-Stimulating Agents

Epoetin alfa reduces anemia but raises clot risk in breast cancer

August 16, 2013

Adding the ESA epoetin alfa to the chemotherapy regimen for high-risk breast cancer improved hemoglobin levels for patients, but it also resulted in increased thrombosis.

CE Courses

Using ESAs in patients with cancer-related anemia

Sarah Wenger, PharmD; Lisa A. Thompson, PharmD, BCOP

February 15, 2012

Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.

Next post in CE Courses

Erythropoietin-Stimulating Agents

Epoetin alfa reduces anemia but raises clot risk in breast cancer

Using ESAs in patients with cancer-related anemia

Inflammatory breast cancer: An atypical breast cancer type